Tiziana Life Sciences Ltd
Index- P/E- EPS (ttm)-0.17 Insider Own43.01% Shs Outstand97.93M Perf Week-1.27%
Market Cap64.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float58.29M Perf Month0.34%
Income-10.50M PEG- EPS next Q- Inst Own5.20% Short Float / Ratio0.11% / 1.26 Perf Quarter-7.41%
Sales- P/S- EPS this Y0.70% Inst Trans-0.07% Short Interest0.07M Perf Half Y-18.44%
Book/sh0.30 P/B2.00 EPS next Y- ROA- Target Price4.00 Perf Year-22.44%
Cash/sh0.24 P/C2.45 EPS next 5Y- ROE- 52W Range0.53 - 1.38 Perf YTD3.59%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.07% Beta0.63
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low17.27% ATR0.05
Employees14 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)47.88 Volatility7.32% 9.80%
OptionableNo Debt/Eq0.00 EPS Q/Q-75.90% Profit Margin- Rel Volume2.07 Prev Close0.60
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume51.99K Price0.62
Recom2.00 SMA20-2.25% SMA500.22% SMA200-14.97% Volume23,989 Change3.33%
Dec-22-20Initiated B. Riley Securities Buy $8
Dec-17-18Initiated Laidlaw Buy
Jan-08-23 08:53AM
Jan-04-23 07:00AM
Jan-03-23 11:11AM
Dec-29-22 05:00PM
05:00PM Loading…
Dec-27-22 05:00PM
Dec-16-22 07:00AM
Dec-15-22 07:00AM
Dec-14-22 06:00AM
Dec-06-22 07:00AM
Dec-05-22 03:00AM
Nov-23-22 10:59AM
Nov-10-22 07:00AM
Nov-04-22 07:00AM
Nov-03-22 07:00AM
07:00AM Loading…
Nov-02-22 07:00AM
Oct-26-22 07:00AM
Oct-19-22 07:00AM
Oct-13-22 05:46AM
Oct-12-22 07:00AM
Sep-29-22 07:00AM
Sep-28-22 07:00AM
Sep-23-22 07:00AM
Sep-21-22 07:30AM
Sep-20-22 06:34AM
Sep-16-22 07:00AM
Sep-15-22 07:00AM
Sep-09-22 07:00AM
Aug-25-22 07:00AM
Aug-17-22 07:00AM
04:24PM Loading…
Aug-16-22 04:24PM
Aug-01-22 09:05AM
Jul-18-22 06:00AM
Jul-15-22 04:15PM
Jun-17-22 04:30PM
Jun-10-22 08:00AM
Jun-09-22 12:53PM
Jun-08-22 12:01PM
Jun-06-22 07:00AM
Jun-01-22 07:00AM
May-24-22 05:56PM
Apr-26-22 11:43AM
Apr-05-22 07:00AM
Mar-25-22 07:00AM
Mar-15-22 02:15PM
Mar-11-22 07:17AM
Mar-10-22 07:00AM
Mar-04-22 07:00AM
Mar-01-22 09:05AM
Feb-10-22 07:00AM
Feb-04-22 07:00AM
Jan-26-22 07:00AM
Jan-24-22 11:12AM
Jan-13-22 07:00AM
Jan-11-22 04:12AM
Jan-10-22 07:00AM
Jan-06-22 04:15PM
Oct-21-21 02:00AM
Oct-20-21 09:40AM
Oct-19-21 09:26AM
Oct-07-21 06:10AM
Sep-28-21 04:19AM
Sep-27-21 12:39PM
Sep-24-21 12:51PM
Sep-20-21 07:45AM
Sep-07-21 02:00AM
Sep-03-21 10:27AM
Sep-02-21 09:42AM
Aug-20-21 02:00AM
Aug-17-21 02:00AM
Aug-16-21 04:36PM
Aug-04-21 01:56AM
Jul-08-21 07:59AM
Jul-02-21 07:58AM
Jul-01-21 05:40AM
Jun-30-21 06:47AM
Jun-25-21 06:15AM
Jun-23-21 02:00AM
Jun-21-21 02:00AM
Jun-17-21 02:00AM
Jun-02-21 02:00AM
May-27-21 07:14AM
May-26-21 06:37AM
May-25-21 06:16AM
May-07-21 02:00AM
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.